Source: Annual Congress 2006 - Novel mechanisms in asthmatic inflammation
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
T. Okada, H. Sagara, K. Akimoto, M. Ota, M. Fueki, N. Fueki, A. Hashii, T. Fukuda (Mibu, Maebashi, Japan). Plasminogen activator inhibitor (PAI)-1 is expressed in human eosinopils stimulated by TGF-β. Eur Respir J 2006; 28: Suppl. 50, 3459

Member's Comments

No comment yet.

Related content which might interest you: Human lung microvascular endothelial cells (HMVEC-L) angiogenic activity is inhibited by stable plasminogen activator inhibitor-1 (PAI-1) mutants via urokinase-dependent pathway Source: Annual Congress 2004 - Lung development and cancer Year: 2004 The regulation of plasminogen activator inhibitor-1 (PAI-1) production with dexamethasone by human lung fibroblasts Source: Eur Respir J 2005; 26: Suppl. 49, 343s Year: 2005 The mechanism of plasminogen activator inhibitor type-1 (PAI-1) Cys mutants inhibitory activity towards lung capillaries endothelial cells (HMVEC-L) Source: Eur Respir J 2005; 26: Suppl. 49, 93s Year: 2005 Pro-urokinase up-regulates the expression of urokinase type plasminogen activator (u-PA) in human pulmonary arterial endothelial cells Source: Eur Respir J 2007; 30: Suppl. 51, 143s Year: 2007 Plasminogen activator inhibitor-1 (PAI-1) mutations of extended half-life time inhibit angiogenic properties of human lung microvascular endothelial cells (HMVEC-L) Source: Eur Respir J 2003; 22: Suppl. 45, 225s Year: 2003 Plasminogen activator inhibitor type 1 (PAI-1) is a negative regulator of lung cancer cells growth due to its anti-proteinase activity Source: Annual Congress 2008 - Novel targets in the molecular pathology of lung cancer and COPD Year: 2008 Lung fibroblasts regulate the urokinase-type plasminogen activator receptor (uPAR) expression of alveolar epithelial cells and endothelial cells Source: Eur Respir J 2006; 28: Suppl. 50, 397s Year: 2006 The effect of prostaglandin (PG) E2 and its receptor antagonists on urokinase-type plasminogen activator (uPA) production by human lung fibroblasts Source: Eur Respir J 2006; 28: Suppl. 50, 811s Year: 2006 Proapoptotic and anti-proliferative effect of the stable plasminogen activator inhibitor type 1 (PAI-1) mutant on the lung cancer and endothelial cells Source: Annual Congress 2009 - What is new in molecular pathology and functional genomics of neoplastic and non-neoplastic lung disease? Year: 2009 Regulation of plasminogen activator activity by inflammatory mediators in lung epithelial cells Source: Eur Respir J 2005; 26: Suppl. 49, 343s Year: 2005 Upregulation of the gene encoding the urokinase-type plasminogen activator (uPA) in respiratory muscles of COPD patients Source: Annual Congress 2004 - Skeletal muscle in respiratory disease Year: 2004 Suppression of plasminogen activator inhibitor-1 by RNA interference attenuates pulmonary fibrosis Source: Annual Congress 2010 - Experimental approaches in pulmonary fibrosis Year: 2010 Enoxaparin reduced ventilation-induced plasminogen activator inhibitor-1 Source: Annual Congress 2009 - Crossing the line: alveolo-capillary barrier control in acute lung injury Year: 2009 Influence of prostaglandin E2 on cell surface urokinase-type plasminogen activator expression and activity in lung adenocarcinoma cell line Source: Eur Respir J 2005; 26: Suppl. 49, 457s Year: 2005 Intra-airway administration of small interfering RNA targeting plasminogen activator inhibitor-1 suppresses allergic asthma in a murine model Source: Annual Congress 2010 - Animal models of asthma and lung inflammation Year: 2010 Peroxiredoxin 6 attenuates lipopolysaccharide-induced plasminogen activatro inhibitor 1 expression by regulating autophagy Source: Annual Congress 2012 - Lung injury and repair: reactive oxygen species and beyond Year: 2012 The relation between plasminogen activator inhibitor-1 (PAI-1) and inflammatory markers in COPD: A possible risk factor of inflammation-induced thrombosis Source: International Congress 2017 – Systemic and airway biomarkers Year: 2017 Soluble urokinase plasminogen activator receptor (suPAR) predicts mortality in exacerbated COPD Source: International Congress 2018 – New predictors of morbidity and mortality in COPD Year: 2018 Urokinase plasminogen activator receptor polymorphisms and airway remodelling in asthma Source: Eur Respir J 2016; 47:1568-1571 Year: 2016 Urokinase type plasminogen activator improves airway inflammation and mucin expression in a murine asthma model Source: Annual Congress 2010 - Mechanisms and modulation of allergic inflammation in the lung Year: 2010